In 2021, the market was estimated at a $34,748.18 million valuation.
There are several key players in the global GI market who are expected to continue dominating the market going forward, including AstraZeneca, Pfizer, Teva and Abbot.
The GI market includes medications and services used for treatment of illnesses including Crohn’s, IBS and colitis.
The report also covers growth in the market across North America, Europe, Asia-Pacific, South America, and the Middle East and Africa.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.